Abstract
Background: 2-Methoxystypandrone (2-MS), isolated from the roots of Polygonum cuspidatum, is a potent dual inhibitor of the STAT3 and NF-κB pathways.
Objective: To investigate the molecular targets and mechanisms of 2-MS.
Method: A biotin-conjugated 2-MS analog, named 2-MS-Biotin, was designed and synthesized. The effects of 2-MS-Biotin on the STAT3 and NF-κB pathways were examined by Western blotting. The cytotoxicity of 2- MS-Biotin was evaluated using real-time cell analysis system. Proteins directly bound to 2-MS-Biotin were pulled down through streptavidin agarose beads and were detected using Western blotting.
Results: 2-MS-Biotin retained the inhibition activities of the parent compound 2-MS on the STAT3 and NF-κB pathways as well as on cancer cell growth. Also, JAK2 and IKK proteins can be effectively pulled down by 2- MS-Biotin.
Conclusion: Using 2-MS-Biotin as a tool, both JAK2 and IKK were identified as the targets of 2-MS.
Keywords: 2-Methoxystypandrone, natural compound, biotin-tagged probe, anticancer drug, JAK2, IKK.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Synthesis of Biotinylated 2-methoxystypandrone and Identification of JAK2 and IKK as its Targets
Volume: 18 Issue: 3
Author(s): Shan Kuang, Zhenhua Sima, Jiawei Liu*, Wuguo Li, Qiaoling Song, Qing Zhang and Qiang Yu*
Affiliation:
- Ministry of Education Key Laboratory of Chinese Medicinal Plants Resource from Lingnan, Research Center of Medicinal Plants Resource Science and Engineering, Guangzhou University of Chinese Medicine, Guangzhou,China
- Division of Tumor Pharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai,China
Keywords: 2-Methoxystypandrone, natural compound, biotin-tagged probe, anticancer drug, JAK2, IKK.
Abstract: Background: 2-Methoxystypandrone (2-MS), isolated from the roots of Polygonum cuspidatum, is a potent dual inhibitor of the STAT3 and NF-κB pathways.
Objective: To investigate the molecular targets and mechanisms of 2-MS.
Method: A biotin-conjugated 2-MS analog, named 2-MS-Biotin, was designed and synthesized. The effects of 2-MS-Biotin on the STAT3 and NF-κB pathways were examined by Western blotting. The cytotoxicity of 2- MS-Biotin was evaluated using real-time cell analysis system. Proteins directly bound to 2-MS-Biotin were pulled down through streptavidin agarose beads and were detected using Western blotting.
Results: 2-MS-Biotin retained the inhibition activities of the parent compound 2-MS on the STAT3 and NF-κB pathways as well as on cancer cell growth. Also, JAK2 and IKK proteins can be effectively pulled down by 2- MS-Biotin.
Conclusion: Using 2-MS-Biotin as a tool, both JAK2 and IKK were identified as the targets of 2-MS.
Export Options
About this article
Cite this article as:
Kuang Shan, Sima Zhenhua, Liu Jiawei*, Li Wuguo, Song Qiaoling, Zhang Qing and Yu Qiang*, Synthesis of Biotinylated 2-methoxystypandrone and Identification of JAK2 and IKK as its Targets, Anti-Cancer Agents in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1871520617666171106123226
DOI https://dx.doi.org/10.2174/1871520617666171106123226 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD44 - a New Cardiovascular Drug Target or Merely an Innocent Bystander?
Cardiovascular & Hematological Disorders-Drug Targets Editorial (Thematic Issue: New Advances of Drug Design in Cancer Disease Part II)
Current Bioactive Compounds Vitamin D, Pit-1, GH, and PRL: Possible Roles in Breast Cancer Development
Current Medicinal Chemistry Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Drug-Induced Mitotic Catastrophe in Cancer Cells
Current Pharmaceutical Design Editorial [ Hot Topic: Oncolytic Virus Therapy (Guest Editor: Hideki Kasuya) ]
Current Cancer Drug Targets Application in Electrochemistry of Graphene-Modified Electrodes
Micro and Nanosystems BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design Therapeutic Targeting of Developmental Signaling Pathways in Medulloblastoma: Hedgehog, Notch, Wnt and Myc
Current Signal Transduction Therapy Of Humans and Hamsters: The Hamster Buccal Pouch Carcinogenesis Model as a Paradigm for Oral Oncogenesis and Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Targeting the Lung: Preclinical and Comparative Evaluation of Anticancer Aerosols in Dogs with Naturally Occurring Cancers
Current Cancer Drug Targets ADAM Proteins- Therapeutic Potential in Cancer
Current Cancer Drug Targets Fungal Mediated Generation of Mammalian Metabolites of Fenofibrate and Enhanced Pharmacological Activity of the Main Metabolite Fenofibric Acid
Drug Metabolism Letters Paclitaxel-tyroserleutide Conjugates Self-assembly into Nanocarrier for Drug Delivery
Letters in Drug Design & Discovery Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry CD133+ Glioblastoma Stem-Like Cells Induce Vascular Mimicry in Vivo
Current Neurovascular Research Mathematical Nanotoxicoproteomics: Quantitative Characterization of Effects of Multi-walled Carbon Nanotubes (MWCNT) and TiO2 Nanobelts (TiO2-NB) on Protein Expression Patterns in Human Intestinal Cells
Current Computer-Aided Drug Design No Effect of Metformin on Ovarian Cancer Survival: A Systematic Review and Meta-Analysis of Cohort Studies
Current Pharmaceutical Design Current Molecularly Targeting Therapies in NSCLC and Melanoma
Anti-Cancer Agents in Medicinal Chemistry